Cg Oncology opened lower at $72.01, compared with its previous close of $72.61. In the last trading session, the stock traded between $67.43 and $73.00. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Cg Oncology is now worth
$ 188.95
Giving a profit of
$ 88.95 (88.95%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-2.38 (-3.28%)
Day High
$73.00
Day Low
$67.43
Day Open
$72.01
Prev Close
$72.61
Volume
10,59,296
1W Return
3.79%
1M Return
11.20%
3M Return
-8.76%
6M Return
1.31%
1Y Return
80.82%
Market Cap ($ Mn)
6,273
PE Ratio
-
PB Ratio
6.37
PEG Ratio
-
ROE
-22.68%
ROCE
-26.74%
EPS (TTM)
$-0.64
1 Week
3.79%
1 Month
11.20%
3 Months
-8.76%
6 Months
1.31%
9 Months
31.15%
Guggenheim maintains buy on CG Oncology, trims price target to $89
Guggenheim maintains a Buy rating on CG Oncology. Price target lowered from $90 to $89. Analyst Michael Schmitz issued the revised recommendation.
3 days agoCG Oncology Q3FY26 Results: Net loss widens to $56.9M, R&D up 41%
Net loss widened to $56.9 million in Q3 2026 from $43.8 million YoY. R&D expenses increased 40.5% to $39.2 million due to clinical trial costs. Cash position stands at $984.5 million, funding operations through 2029. PIVOT-006 Phase 3 topline data expected in November 2026.
6 days agoKuehn Law investigates CG Oncology for potential fiduciary breach
Kuehn Law is investigating CG Oncology for potential breach of fiduciary duties. The inquiry focuses on allegations of self-dealing by officers and directors. Shareholders may be entitled to damages and corporate governance reforms. The law firm offers free consultations and covers all case costs.
1mo agoKuehn Law probes CG Oncology for alleged fiduciary duty breaches
Kuehn Law, PLLC has launched an investigation into alleged fiduciary duty breaches by CG Oncology, Inc. (NASDAQ: CGON) officers and directors. The probe focuses on potential self-dealing, with possible outcomes including shareholder damages and governance reforms. Investors are urged to contact the firm for a free consultation as statutory deadlines may apply.
2mo agoCG Oncology Q2 Results: EPS Misses Estimate, Sales Beat
CG Oncology's Q2 results show a mixed bag for investors: while sales of $1.157 million crushed estimates by over 221%, the company missed EPS expectations with a loss of $(0.90) per share, a 66.67% deterioration from the prior year's $(0.54).
3mo agoKuehn Law probes CG Oncology for self-dealing breaches
Kuehn Law, PLLC is investigating CG Oncology, Inc. (NASDAQ: CGON) for alleged fiduciary breaches involving self-dealing by officers and directors. The firm warns that shareholders may face limited time to enforce their rights and seek damages. Investors are urged to contact Sophia Anne Silayan at (833) 672-0814 or via email for free consultation, as the firm covers all case costs. This probe underscores critical governance risks for the company.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Cg Oncology is now worth
$ 188.95
Giving a profit of
$ 88.95 (88.95%)
Note: Past profits do not guarantee future returns.
